Start with how little human research exists.
The Food and Drug Administration (FDA) handles U.S. medicine reviews.
The FDA’s review, as of September 28, 2026, described five human studies involving BPC-157.
Across those studies, roughly eighty people received the substance.
Two studies used a comparison group: people given another treatment to judge the BPC-157 results against.
Neither study had appeared as a complete published paper.
Read the basisFDA summary of human experience, PDFAn improvement does not explain its cause.
Small reports described improvements in knee pain and a painful bladder condition after BPC-157.
Neither report included a comparison group, so neither can show that this substance caused the change.
Read the basisFDA review of the small reports, PDF